Inhibitor development in previously treated hemophilia A patients: A systematic review, meta-analysis, and meta-regression

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 9, 2013, Pages 1655-1662

  Xi, M ^a   Makris, M ^b   Marcucci, M ^a   Santagostino, E ^c   Mannucci, P M ^c   Iorio, A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Factor VIII; Hemophilia A; Inhibitors; Review; Risk factors; Systematic

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HEMOPHILIA A; HUMAN; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

FACTOR VIII; HEMOPHILIA A; INHIBITORS; REVIEW; RISK FACTORS; SYSTEMATIC;

FACTOR VIII; HEMOPHILIA A; HUMANS;

EID: 84883747381     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12335     Document Type: Article

References (29)

1. Mannucci P, Tuddenham EGD. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Hay CRM, Palmer B, Chalmers E, Liesner R, Maclean R, Rangarajan S, Williams M, Collins PW. Incidence of factor VII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
3. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Scientific and Standardization Committee Communication. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis-ISTH. Thromb Haemost 2001; 85: 560.
4. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
5. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
6. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16: 66-70.
7. White GC, DiMichele D, Mertens K, Negrier C, Peake IR, Prowse C, Schwaab R, Yoshioka A, Ingerslev J. Utilization of previously treated patients (PTPs), non-infected patients (NIPs), and previously untreated patients (PIPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the scientific subcommittee on factor VIII and factor IX. Thromb Haemost 1999; 81: 462.
8. Aledort LM. Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment. J Thromb Haemost 2011; 9: 423-7.
9. Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120: 720-7.
10. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
11. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A metaanalysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-92.
12. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knofler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Gottl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
13. Makris M, Calizzani G, Fischer K, Gilman EA, Hay CRM, Lassila R, Lambert T, Ludlam CA, Mannucci PM. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127: S22-5.
14. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990; 6: 5-30.
15. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
16. Rosendaal FR, Nieuwenhuis HK, van Den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PF, Briet E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
17. ® solvent detergent in previously treated patients with severe haemophilia A. Haemophilia 2007; 13: 9-11.
18. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
19. Rothschild C, Scharrer I, Brackmann HH, Stieltjes N, Vicariot M, Torchet MF, Effenberger W. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8: 10-4.
20. Zanon E, Zerbinati P, Girolami B, Bertomoro A, Girolami A. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates. Blood Coagul Fibrinolysis 1999; 10: 117-20.
21. Wang XF, Zhao YQ, Yang RC, Wu JS, Sun J, Zhang XS, Ding QL, Ge HL, Wang HL. The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A. Haemophilia 2010; 16: 632-9.
22. Roussel-Robert V, Torchet MF, Legrand F, Rothschild C, Stieltjes N. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. J Thromb Haemost 2003; 1: 2445-6.
23. Keeling D. Switching between full-length and B-domain-deleted factor VIII and the risk of inhibitors. Haemophilia 2006; 12: 690-1.
24. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2009; 8: 83-9.
25. Fukutake K, Musso R, Young J, Norenberg C. Inhibitor formation with sucrose-formulated recombinant factor VIII in patients with hemophilia A: results from postmarketing surveillance studies. J Thromb Haemost 2009; 7: 823.
26. Petrini P, Rylander C. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto® utilizing a computer-aided diary: a Nordic multicentre study. Haemophilia 2009; 15: 175-83.
27. Taki M, Fukutake K, Hanabusa H, Takamatsu J, Shima M, Shirahata A. Post-authorization safety surveillance (PASS) program of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) for Japanese hemophilia A patients. J Thromb Haemost 2009; 7: 1125.
28. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia 1999; 5: 9-16.
29. Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 2005; 11: 292-3.